Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identification and characterization of echinocandin potentiators to combat drug-resistant Candida species.
EF 2021-22
Résumé
Although largely overlooked, fungi cause deadly systemic infections in a growing population of immunocompromised patients that encompass high-dose corticosteroids users, solid organ transplant recipients, and those infected with HIV. Candida albicans is a leading cause of these infections with mortality rates of ~40%. Currently, there are only three classes of drugs used to treat systemic fungal infections: azoles, polyenes, and echinocandins. The echinocandins are the only new class of antifungal drug to reach clinics in decades, and while the emergence of drug-resistance fungi, including echinocandin-resistant Candida species, threatens global public health, current antifungal treatments remain insufficient. Drug combination therapies can reduce host toxicities by enabling a reduction of drug dosages and can reduce the likelihood of developing resistance. In a quest to identify novel therapies to combat C. albicans infections, I screened the Boston University Centre for Molecular Discovery (BU-CMD) library of 3,936 chemically diverse compounds against an echinocandin-resistant isolate of C. albicans alone and in combination with the echinocandin, caspofungin. Through this approach, I identified 31 compounds with single-agent activity and 35 compounds that enhanced the activity of the echinocandin caspofungin. The mechanism of action of these prioritized compounds will be assessed using genetic approaches that utilize a C. albicans mutant library. Finally, hit compounds will be assessed for their therapeutic potential by evaluating toxicity against human cells as well as through mouse models of systemic candidiasis. My project will reveal much-needed novel therapeutic strategies to combat drug-resistant fungal pathogens threatening thousands of lives around the globe.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466683
Name
Fallah Sara
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification and characterization of echinocandin potentiators to combat drug-resistant Candida species.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Fungal Drug Discovery; Anti-Fungal Resistance; Chemical Screening; Combination Therapy; Drug Enhancers; Echinocandins; Fungal Infections; Fungal Pathogens; Infectious Disease; Microbiology
Abstract
Although largely overlooked, fungi cause deadly systemic infections in a growing population of immunocompromised patients that encompass high-dose corticosteroids users, solid organ transplant recipients, and those infected with HIV. Candida albicans is a leading cause of these infections with mortality rates of ~40%. Currently, there are only three classes of drugs used to treat systemic fungal infections: azoles, polyenes, and echinocandins. The echinocandins are the only new class of antifungal drug to reach clinics in decades, and while the emergence of drug-resistance fungi, including echinocandin-resistant Candida species, threatens global public health, current antifungal treatments remain insufficient. Drug combination therapies can reduce host toxicities by enabling a reduction of drug dosages and can reduce the likelihood of developing resistance. In a quest to identify novel therapies to combat C. albicans infections, I screened the Boston University Centre for Molecular Discovery (BU-CMD) library of 3,936 chemically diverse compounds against an echinocandin-resistant isolate of C. albicans alone and in combination with the echinocandin, caspofungin. Through this approach, I identified 31 compounds with single-agent activity and 35 compounds that enhanced the activity of the echinocandin caspofungin. The mechanism of action of these prioritized compounds will be assessed using genetic approaches that utilize a C. albicans mutant library. Finally, hit compounds will be assessed for their therapeutic potential by evaluating toxicity against human cells as well as through mouse models of systemic candidiasis. My project will reveal much-needed novel therapeutic strategies to combat drug-resistant fungal pathogens threatening thousands of lives around the globe.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fallah, Sara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~